Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 3, 2006, Pages 560-565

  Nasser, N J ^a,b   Sarig, G ^c   Brenner, B ^c   Nevo, E ^b   Goldshmidt, O ^a   Zcharia, E ^d   Li, J P ^e   Vlodavsky, I ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cancer progression; Coagulation; Heparanase; Heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARANASE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; GEL PERMEATION CHROMATOGRAPHY; MOLECULAR SIZE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; FACTOR XA; GLUCURONIDASE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS;

EID: 33645983628     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01792.x     Document Type: Article

References (43)

1. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57: 159-206.
2. Robinson HC, Horner AA, Hook M, Ogren S, Lindahl U. A proteoglycan form of heparin and its degradation to single-chain molecules. J Biol Chem 1978; 253: 6687-93.
3. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-77.
4. Parish CR, Freeman C, Hulett MD. Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 2001; 1471: 0M99-108.
5. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001; 108: 341-7.
6. Nakajima M, Irimura T, Nicolson GL. Heparanases and tumor metastasis. J Cell Biochem 1988; 36: 157-67.
7. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000; 25: 349-51.
8. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999; 5: 793-802.
9. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999; 5: 803-9.
10. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun 1999; 261: 183-7.
11. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. J Biol Chem 1999; 274: 24153-60.
12. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G, Ng S, Mason S, Snell D, Schofield D, Gong H, Townsend R, Gallagher J, Page M, Parekh R, Stubberfield C. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochemical J 2003; 373: 423-35.
13. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophy Res Commun 2003; 308: 885-91.
14. Jacobsson KG, Lindahl U. Degradation of heparin proteoglycan in cultured mouse mastocytoma cells. Biochem J 1987; 246: 409-15.
15. Gong F, Jemth P, Escobar Galvis ML, Vlodavsky I, Horner A, Lindahl U, Li JP. Processing of macromolecular heparin by heparanase. J Biol Chem 2003; 278: 35152-8.
16. Ogren S, Lindahl U. Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 1975; 250: 2690-7.
17. Thunberg L, Backstrom G, Wasteson A, Robinson HC, Ogren S, Lindahl U. Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta- d -glucuronidases. J Biol Chem 1982; 257: 10278-82.
18. Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998; 273: 18770-7.
19. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K. Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002; 277: 42488-95.
20. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30
21. Hemker HC, Beguin S. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990; 20: 81-92.
22. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkuhler C. Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 2004; 43: 1862 -73.
23. Thunberg L, Backstrom G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
24. Lindahl B, Eriksson L, Lindahl U. Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. Biochem J 1995; 306: 177-84.
25. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, Metzger S, Vlodavsky I, Kisilevsky R, Lindahl U. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc Natl Acad Sci USA 2005; 102: 6473-77.
26. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, Friedmann Y, Weinstein T, Li JP, Lindahl U, Vlodavsky I. Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 2004; 18: 252-63.
27. Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR, Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis 1992; 12: 112-27.
28. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 1994; 14: 290-302.
29. Parish CR, Coombe DR, Jakobsen KB, Bennett FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int J Cancer 1987; 40: 511-18.
30. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999; 59: 3433-41.
31. Bartlett MR, Cowden WB, Parish CR. Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets. J Leukocyte Biol 1995; 57: 207-13.
32. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98: 3352-57.
33. Kakkar A. An expanding role for antithrombotic therapy in cancer patients. Cancer Treatment Rev 2003; 29: 23-6.
34. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2004; 2: 1263-5.
35. Freeman C, Parish CR. Human platelet heparanase: Purification, characterization and catalytic activity. Biochem J 1998; 330: 1341-50.
36. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, Vlodavsky I. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987; 70: 551-57.
37. Ernst S, Langer R, Cooney CL, Sasisekharan R. Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol 1995; 30: 387-444.
38. Heres EK, Horrow JC, Gravlee GP, Tardiff BE, Luber Jr J, Schneider J, Barragry T, Broughton R. A dose-determining trial of heparinase-I (Neutralase) for heparin neutralization in coronary artery surgery. Anesth Analg 2001; 93: 1446-52.
39. Levy JH. Heparin resistance and antithrombin: Should it still be called heparin resistance ? J Cardiovasc Anesth 2004; 18: 129-30.
40. Deitcher SR. Cancer and thrombosis: Mechanisms and treatment. J Thromb Thrombolysis 2003; 16: 21-31.
41. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer 2001; 95: 295-301.
42. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001; 61: 4655-59.
43. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA. Human heparanase-1 gene expression in pancreatic adenocarcinoma. J Gastrointest Surg 2002; 6: 167-72.